Atrinsic Inc. (NASDAQ:PTIX) Short Interest Down 17.7% in December

Atrinsic Inc. (NASDAQ:PTIX) was the target of a significant drop in short interest during the month of December. As of December 31st, there was short interest totaling 50,768 shares, a drop of 17.7% from the December 15th total of 61,712 shares. Based on an average daily trading volume, of 53,322 shares, the short-interest ratio is presently 1.0 days. Approximately 2.9% of the shares of the company are short sold. Approximately 2.9% of the shares of the company are short sold. Based on an average daily trading volume, of 53,322 shares, the short-interest ratio is presently 1.0 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of Atrinsic in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Atrinsic Stock Down 15.1%

NASDAQ PTIX opened at $0.50 on Wednesday. The firm has a market cap of $968,854.50, a P/E ratio of -0.06 and a beta of 0.51. The company’s 50 day moving average is $1.42 and its 200-day moving average is $2.59. Atrinsic has a 12-month low of $0.26 and a 12-month high of $14.28.

Atrinsic (NASDAQ:PTIX) last released its quarterly earnings data on Wednesday, November 26th. The company reported ($0.47) earnings per share for the quarter.

Atrinsic Company Profile

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc is headquartered in New York, New York.